Print
Health Care

PPD Reports Major Upticks In Third Quarter Financial Indicators

By Jenny Callison, posted Oct 28, 2020
With key indicators – such as earnings, new orders and order backlog – on the rise, PPD Chairman and CEO David Simmons announced that the third quarter of 2020 has been a “strong quarter” for the global clinical research organization based in Wilmington.
 
“We have continued to focus on executing for our customers as we navigate through the pandemic,” Simmons stated in a news release Tuesday. “This is evident in our continued momentum with double-digit growth in net authorizations, revenue and adjusted EBITDA [earnings before interest, taxes, depreciation and amortization] over last year.

"Furthermore, we are proud that PPD is continuing to play a leading role in the development of vaccines and therapies for COVID-19, now having won more than 140 awards for work associated with the virus.” 


In PPD’s earnings call Wednesday, Simmons said that COVID-related work has represented about 20% of its authorizations this past quarter. Even disregarding that segment of PPD’s work, growth was up in Q3 year over year, he said, attributing that growth partly to the company’s accelerated pace in starting work after contract awards.
 
Highlights of PPD’s third-quarter 2020 financial status include:
  • The company’s net authorizations for new work totaled $1.2 billion, up 33.3% compared to $900 million at the end of Q3 2019. 
  • This past quarter’s revenue was more than $1.2 billion, up 20.5% over Q3 2019 revenue of just over $1 billion. 
  • Net income attributable to common stockholders for the quarter was $52 million, or 15 cents per diluted share, compared to $26.7 million, or 9 cents per diluted share, for the third quarter of 2019. 
  • The most recent quarter’s book-to-bill ratio was 1.35-times, compared to 1.14-times for Q3 2019. 
  • PPD ended Q3 2020 with what the company said was a record backlog of nearly $7.9 billion, a year-over-year increase of almost 16%. The backlog at the end of Q3 2019 was $6.8 billion.
 
PPD finished the quarter with $803 million in cash and total liquidity of $1.1 billion, “which represents the strongest quarter-end liquidity position in over 10 years,” officials stated.
 
Indicators were strong enough in mid-September that PPD revised its financial estimates upward, Simmons said during the earnings call, adding that those estimates were exceeded.
 
He and other company officials are bullish about the future.
 
Assuming no significant reduction in site access, patient enrollment and other key operating metrics in Q4 as a result of COVID-19, and that there are no major delays or cancellations of COVID-19 studies during the fourth quarter from safety concerns or other issues, PPD expects revenues for the fourth quarter to be in the $1.25 billion to nearly $1.3 billion range, a year-over-year increase of between 20% and 24%.
 
Looking at Fiscal Year 2020 as a whole, PPD expects revenues of between nearly $4.5 billion and $4.6 billion, which would be an increase of between 13.5% and 14.5% over those of Fiscal 2019.
 
Simmons said PPD is at a competitive advantage in the CRO industry because of its expertise and experience globally, its strategic investments aimed at improving both the quality and quantity of the work it performs, its collaborative customer engagement model and the “talent and tenure” of the company’s team.

The company’s adaptability in the face of coronavirus-related changes this year, he said, also worked to PPD’s advantage.

PPD's stock, which trades on Nasdaq, ended the day Wednesday at $33.16 per share. The stock price has shown a gradual rise since the company's debut on the exchange at about $24 per share.
Ico insights

INSIGHTS

SPONSORS' CONTENT
Untitleddesign2 9202334730

Best in the State: Providing Quality Care to Medicare and Medicaid Patients Allows Novant Health New Hanover Regional Medical Center to Reinvest in Community

Novant Health - New Hanover Regional Medical Center Novant Health
Untitleddesign7

Getting Your Community Ready for Spring and Summer

Dave Orr - Community Association Management Services
Georgiarowe

Salling and Tate Dentistry Launches Annual "Gunner’s Runners" Shoe Collection Event, Aiming to Surpass Last Year's Success

Georgia Rowe - Wide Open Tech

Trending News

Conservation Group Signs $8M Deal To Buy The Point On Topsail Island

Audrey Elsberry - Mar 26, 2024

National Organization Bestows Top Award On Cape Fear Professional Women In Building

Staff Reports - Mar 26, 2024

Engineering Firm Hires Four Employees

Staff Reports - Mar 26, 2024

N.C. Ports Officials React To Baltimore Bridge Collapse

Audrey Elsberry - Mar 26, 2024

NCino's Fourth-quarter Earnings Signal Rebound From Liquidity Crisis

Audrey Elsberry - Mar 27, 2024

In The Current Issue

Topsail-area Realtors Share Updates

Pender County Realtors recently shared updates about the coastal market at an event hosted by the Wilmington-Cape Fear Home Builders Associa...


Berries, A Battlefield And More In Pender

The N.C. Blueberry Festival, founded in 2003, is one of several events in Pender County that have drawn more attention over the years....


MADE: Polyhose Inc.

Polyhose manufactures and fabricates hose protection, paint hose assemblies and rubber hydraulic assemblies from its Pender County facility....

Book On Business

The 2024 WilmingtonBiz: Book on Business is an annual publication showcasing the Wilmington region as a center of business.

Order Your Copy Today!


Galleries

Videos

2023 Power Breakfast: Major Developments